AU2022257344A1 - Transdermal delivery of cannabidiol - Google Patents

Transdermal delivery of cannabidiol Download PDF

Info

Publication number
AU2022257344A1
AU2022257344A1 AU2022257344A AU2022257344A AU2022257344A1 AU 2022257344 A1 AU2022257344 A1 AU 2022257344A1 AU 2022257344 A AU2022257344 A AU 2022257344A AU 2022257344 A AU2022257344 A AU 2022257344A AU 2022257344 A1 AU2022257344 A1 AU 2022257344A1
Authority
AU
Australia
Prior art keywords
days
once
pain
transdermal
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022257344A
Other languages
English (en)
Inventor
Marina BOROVINSKAYA
Tamanna LATHER
Nisarg MODI
Fotios M. Plakogiannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/227,591 external-priority patent/US12121617B2/en
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of AU2022257344A1 publication Critical patent/AU2022257344A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022257344A 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol Pending AU2022257344A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/227,591 US12121617B2 (en) 2019-10-14 2021-04-12 Transdermal delivery of cannabidiol
US17/227,591 2021-04-12
PCT/IB2022/053276 WO2022219468A1 (fr) 2021-04-12 2022-04-07 Administration transdermique de cannabidiol

Publications (1)

Publication Number Publication Date
AU2022257344A1 true AU2022257344A1 (en) 2023-10-26

Family

ID=83640369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022257344A Pending AU2022257344A1 (en) 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol

Country Status (7)

Country Link
EP (1) EP4322931A1 (fr)
JP (1) JP2024513961A (fr)
CN (1) CN117460503A (fr)
AU (1) AU2022257344A1 (fr)
CA (1) CA3214228A1 (fr)
MX (1) MX2023011948A (fr)
WO (1) WO2022219468A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5801794B2 (ja) * 2009-04-28 2015-10-28 ジネルバ ファーマシューティカルズ， インコーポレイティド カンナビジオールの製剤及びその使用方法
WO2010126501A1 (fr) * 2009-04-29 2010-11-04 University Of Kentucky Research Foundation Compositions contenant un cannabinoïde et leurs méthodes d'utilisation
WO2011026144A1 (fr) * 2009-08-31 2011-03-03 Alltranz Inc. Utilisation de promédicaments de cannabidiol pour administration topique et transdermique avec des micro-aiguilles
AU2018318425A1 (en) * 2017-08-14 2020-02-27 Zynerba Pharmaceuticals, Inc. Methods of treatment of osteoarthritis with transdermal cannabidiol gel
US20200289458A1 (en) * 2017-09-22 2020-09-17 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
US20220287964A1 (en) * 2019-08-05 2022-09-15 Cs Medica A/S Topical formulations comprising cannabidiol, method of prep aring the composition and use thereof
AU2020366147B2 (en) * 2019-10-14 2024-09-05 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3178878A1 (fr) * 2020-04-20 2021-10-28 Fotios M. Plakogiannis Formulations pharmaceutiques transdermiques et/ou topiques comprenant du cannabidiol et/ou du tetrahydrocannabinol pour le traitement de la douleur chronique
WO2022003623A1 (fr) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Formulations pharmaceutiques transdermiques pour le traitement de la sclérose en plaques
EP4196114A4 (fr) * 2020-08-17 2024-10-30 Pike Therapeutics Inc Formulations pharmaceutiques transdermiques de cannabinoïdes
AU2021393122A1 (en) * 2020-12-03 2023-06-29 Pike Therapeutics Inc. Transdermal pharmaceutical formulations comprising cbd or thc for the treatment of cancer

Also Published As

Publication number Publication date
WO2022219468A1 (fr) 2022-10-20
CA3214228A1 (fr) 2022-10-20
JP2024513961A (ja) 2024-03-27
EP4322931A1 (fr) 2024-02-21
CN117460503A (zh) 2024-01-26
MX2023011948A (es) 2023-10-17

Similar Documents

Publication Publication Date Title
AU2020366147B2 (en) Transdermal delivery of cannabidiol
CA3178878A1 (fr) Formulations pharmaceutiques transdermiques et/ou topiques comprenant du cannabidiol et/ou du tetrahydrocannabinol pour le traitement de la douleur chronique
US12121617B2 (en) Transdermal delivery of cannabidiol
CA3187582A1 (fr) Compositions pharmaceutiques et methodes de traitement de la maladie de parkinson
WO2022003623A1 (fr) Formulations pharmaceutiques transdermiques pour le traitement de la sclérose en plaques
EP4041209A1 (fr) Compositions transdermiques comprenant du cannabidiol (cbd) destinées à être utilisées dans le traitement de troubles épileptiques
EP4037663A1 (fr) Administration transdermique de dronabinol
WO2022219468A1 (fr) Administration transdermique de cannabidiol
US12016829B2 (en) Pharmaceutical composition and method for treating seizure disorders
AU2022255944A1 (en) Pharmaceutical composition and method for treating seizure disorders
AU2022260813A1 (en) Transdermal pharmaceutical formulations for the treatment of chronic pain